

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
18 November 2021 (18.11.2021)



(10) International Publication Number
WO 2021/231174 A1

(51) International Patent Classification:

C07D 401/14 (2006.01) *A61P 35/04* (2006.01)
C07D 231/16 (2006.01) *A61K 31/501* (2006.01)

(21) International Application Number:

PCT/US2021/031091

(22) International Filing Date:

06 May 2021 (06.05.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:



63/022,475	09 May 2020 (09.05.2020)	US
63/149,143	12 February 2021 (12.02.2021)	US
63/177,378	20 April 2021 (20.04.2021)	US

(71) Applicant: **ARVINAS OPERATIONS, INC.** [US/US]; 5 Science Park, 395 Winchester Avenue, New Haven, Connecticut 06511 (US).

(72) Inventors: **DONG, Hanqing**; 248 Opening Hill Road, Madison, Connecticut 06443 (US). **DUGUID, Robert J.**; 68 Patterson Drive, Glenmont, New York 12077 (US). **JAGER, Casey Keith**; 1830 NW Glassow Drive, Bend, Oregon 97703 (US). **KAUSHAL, Aditya Mohan**; 2267 NE Indigo Lane, Bend, Oregon 97701 (US). **KENNEDY, Samuel Elliott**; 62072 Wolcott Place, Bend, Oregon 97701 (US). **NEESER, Miranda Annell**; 2155 NE 6th Street, Apt. 46, Bend, Oregon 97701 (US). **REEVE, Maxwell Marco**; 465 Goose Lane, Guilford, Connecticut 06437 (US). **REO, Joseph P.**; 1211 Evergreen Road, Riegelsville, Pennsylvania 18077 (US). **ZAHEDI, Mohammad Mehdi**; 15 Harmony Hill Road, Apt. 2C, Albany, New York 12203 (US). **KATTUBOINA, Venkata A.**; 5 Wampanoag Way, Westford, Massachusetts 01886 (US). **ALLAN, Laura**

(54) Title: METHODS OF MANUFACTURING A BIFUNCTIONAL COMPOUND, ULTRAPURE FORMS OF THE BIFUNCTIONAL COMPOUND, AND DOSAGE FORMS COMPRISING THE SAME

FIG. 1



(Compound A).

(57) Abstract: The present disclosure relates to ultra-pure forms, polymorphs, amorphous forms, and formulations of N-[(1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl]-6-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazin-1-yl)methyl]piperidin-1-yl]pyridazine-3-carboxamide, referred to herein as Compound A. The present disclosure also relates methods of manufacturing and purifying the same, as well as intermediates useful in the synthesis of Compound A. The ultra-pure forms, polymorphs, amorphous forms, and formulations of Compound A can be used as therapeutic agents for the treatment of various diseases and conditions such as cancer.

[Continued on next page]

E.N.; 141 Easter Langside Drive, Dalkeith EH222FR (GB).
CHEN, Chungpin Herman; 92 Joshua Trail, Madison, Connecticut 06443 (US). **GROSSO, John A.**; 22 Newport Drive, Princeton Jct., New Jersey 08550 (US). **HASKELL, III, Royal J.**; 71R Banta Lane, Durham, Connecticut 06422 (US). **LLOYD, Rhys**; 14 Sandpiper Crescent, Coatbridge, North Lanarkshire ML54FF (GB). **REECE, Hayley**; 5A Miners Walk, Dalkeith EH222AL (GB). **ROBERTSON, Jerod**; 1245 Park Street, Robbinsville, New Jersey 08691 (US). **QIU, Yuping**; 7 Hickory Court, Princeton Junction, New Jersey 08550 (US).

(74) **Agent: ELRIFI, Ivor** et al.; 1299 Pennsylvania Avenue, NW, Suite 700, Washington, District of Columbia 20004-2400 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*